Transdermal drug delivery system
A transdermal drug delivery system is provided that includes a drug-in-adhesive matrix layer and a backing layer. The matrix layer includes an active pharmaceutical ingredient, a cross-linked polyvinylpyrrolidone binder, a mesoporous silicon dioxide filler, and a pressure sensitive adhesive, while the backing layer forms an exterior facing-surface of the delivery system. The ratio of the mesoporous silicon dioxide filler to the cross-linked polyvinylpyrrolidone binder ranges from about 1:1 to about 1:8. As a result of the specific components of the matrix layer and the amounts in which they are utilized, the resulting delivery system, which can include a homogeneous dispersion of the active pharmaceutical ingredient in the formulation, is capable of delivering the active pharmaceutical ingredient over a period of up to about 7 days in a generally constant and controlled fashion. Further, the only layer that contemplates the use of an adhesive component is the drug-in-adhesive matrix layer.
1. A transdermal drug delivery system comprising:
a drug-in-adhesive matrix layer including an active pharmaceutical ingredient, a cross-linked polyvinylpyrrolidone binder, a mesoporous silicon dioxide filler, and a pressure sensitive adhesive; and
a backing layer, wherein the backing layer forms an exterior facing-surface of the transdermal drug delivery system;
wherein the ratio of the mesoporous silicon dioxide filler to the cross-linked polyvinylpyrrolidone binder ranges from 1 part mesoporous silicon dioxide filler to 1 part cross-lined polyvinylpyrrolidone binder up to 1 part mesoporous silicon dioxide filler to 8 parts cross-linked polyvinylpyrrolidone binder.
2. The transdermal drug delivery system of claim 1 , wherein the mesoporous silicon dioxide filler has a pH ranging from about 6 to about 8.
3. The transdermal drug delivery system of claim 1 , wherein the mesoporous silicon dioxide filler is in the form of particles having an average particle size ranging from about 1 micrometer to about 10 micrometers.
4. The transdermal drug delivery system of claim 3 , wherein the mesoporous particles have an average pore size ranging from about 2 nanometers to about 50 nanometers.
5. The transdermal drug delivery system of claim 1 , wherein the cross-linked polyvinylpyrrolidone binder is in the form of particles having an average particle size ranging from about 1 micrometer to about 40 micrometers.
6. The transdermal drug delivery system of claim 1 , wherein the cross-linked polyvinylpyrrolidone binder is in the form of particles having a bulk density ranging from about 0.10 g/mL to about 0.25 g/mL.
7. The transdermal drug delivery system of claim 1 , wherein the cross-linked polyvinylpyrrolidone binder is in the form of particles having a surface area ranging from about 0.5 m 2 /g to about 20 m 2 /g.
8. The transdermal drug delivery system of claim 1 , wherein the pressure sensitive adhesive includes polyisobutylene.
9. The transdermal drug delivery system of claim 1 , wherein the active pharmaceutical ingredient is clonidine.
10. The transdermal drug delivery system of claim 9 , wherein the clonidine is present in the transdermal drug delivery system at a concentration ranging from about 0.2 mg/cm 2 to about 1 mg/cm 2 .
11. The transdermal drug delivery system of claim 1 , wherein the drug-in-adhesive matrix layer further includes an oil-based plasticizer.
12. The transdermal drug delivery system of claim 1 , further comprising a release liner, wherein the release liner is disposed on a skin-contacting surface of the drug-in-adhesive matrix layer.
13. The transdermal drug delivery system of claim 1 , wherein the active pharmaceutical ingredient is delivered to a patient at a constant rate for up to about 7 days.
14. The transdermal drug delivery system of claim 1 , wherein the active pharmaceutical ingredient is homogeneously distributed throughout the drug-in-adhesive matrix layer, wherein the drug-in-adhesive matrix layer is the only adhesive-containing component in the transdermal drug delivery system.
15. A method of providing transdermal delivery of an active pharmaceutical ingredient to a patient for up to about seven days, the method comprising:
providing the transdermal delivery system according to claim 1 ,
affixing the transdermal delivery system to the patient; and
transdermally delivering the active pharmaceutical ingredient to the patient.
16. A method of making a drug-in-adhesive matrix layer for a transdermal drug delivery system, the method comprising:
providing an active pharmaceutical ingredient;
adding a cross-linked polyvinylpyrrolidone binder to the active pharmaceutical ingredient to form a blend;
adding a polar solvent to the blend;
adding a pressure sensitive adhesive dissolved in a non-polar solvent to the blend;
adding a plasticizer to the blend; and
adding a mesoporous silicon dioxide filler to the blend such that the ratio of the mesoporous silicon dioxide filler to the cross-linked polyvinylpyrrolidone binder ranges from 1 part mesoporous silicon dioxide filler to 1 part cross-linked polyvinylpyrrolidone binder up to 1 part mesoporous silicon dioxide filler to 8 parts cross-linked polyvinylpyrrolidone binder.
17. The method of claim 16 , wherein the mesoporous silicon dioxide filler has a pH ranging from about 6 to about 8.
18. The method of claim 16 , wherein the mesoporous silicon dioxide filler is in the form of particles having an average particle size ranging from about 1 micrometer to about 10 micrometers.
19. The method of claim 16 , wherein the cross-linked polyvinylpyrrolidone binder is in the form of particles having an average particle size ranging from about 1 micrometer to about 40 micrometers.
20. The method of claim 16 , wherein the polar solvent is ethyl acetate and the non-polar solvent is heptane.